Vanda Pharmaceuticals Inc. (VNDA)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Vanda Pharmaceuticals Inc. reported revenue of $216.10M, up 8.7% from the prior year. The company ran a net loss, with a net margin of -102.0%. It held $488.95M in total assets against $161.76M in total liabilities.
Key ratios (FY2025)
-70.0%
Operating margin
-102.0%
Net margin
-67.4%
Return on equity
+8.7%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $216.10M | $198.77M | $192.64M | $254.38M | $268.68M | $248.17M | $227.19M | $193.12M | $165.08M | $146.02M |
| Operating Income | -$151.17M | -$40.66M | -$13.95M | $6.33M | $42.16M | $27.24M | $22.81M | $21.74M | -$16.90M | -$18.57M |
| Net Income | -$220.47M | -$18.90M | $2.51M | $6.28M | $33.15M | $23.34M | $115.55M | $25.21M | -$15.57M | -$18.01M |
| EPS (Diluted) | $-3.74 | $-0.33 | $0.04 | $0.11 | $0.58 | $0.42 | $2.11 | $0.48 | $-0.35 | $-0.41 |
| Total Assets | $488.95M | $656.20M | $648.44M | $634.25M | $593.79M | $533.46M | $483.75M | $332.13M | $205.43M | $210.37M |
| Total Liabilities | $161.76M | $117.66M | $103.53M | $107.05M | $88.86M | $80.19M | $72.80M | $56.71M | $74.04M | $79.04M |
| Shareholders' Equity | $327.19M | $538.55M | $544.91M | $527.20M | $504.93M | $453.27M | $410.94M | $275.42M | $131.39M | $131.33M |
| Cash & Equivalents | $84.85M | $102.32M | $135.82M | $135.03M | $52.07M | $61.03M | $45.07M | $61.01M | $33.63M | $40.43M |
| Operating Cash Flow | -$109.44M | -$15.76M | $12.80M | $31.98M | $64.21M | $51.77M | $45.95M | $29.99M | -$1.98M | — |
| Capital Expenditures | $998.0K | $490.0K | $383.0K | $679.0K | $552.0K | $1.79M | $1.02M | $368.0K | $1.66M | $1.41M |
| Shares Outstanding | 58.93M | 58.15M | 57.56M | 56.98M | 56.92M | 55.19M | 54.85M | 53.05M | 44.74M | 43.45M |